CA3172596A1 - Pulmonary fibrosis medicine containing pyrazole derivative - Google Patents
Pulmonary fibrosis medicine containing pyrazole derivative Download PDFInfo
- Publication number
- CA3172596A1 CA3172596A1 CA3172596A CA3172596A CA3172596A1 CA 3172596 A1 CA3172596 A1 CA 3172596A1 CA 3172596 A CA3172596 A CA 3172596A CA 3172596 A CA3172596 A CA 3172596A CA 3172596 A1 CA3172596 A1 CA 3172596A1
- Authority
- CA
- Canada
- Prior art keywords
- pyrazol
- pyridin
- hydrochloride salt
- compound
- pheny1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2020-0044598 | 2020-04-13 | ||
| KR20200044598 | 2020-04-13 | ||
| KR10-2021-0036863 | 2021-03-22 | ||
| KR1020210036863A KR102386097B1 (ko) | 2020-04-13 | 2021-03-22 | 피라졸 유도체의 폐섬유증 치료제 |
| PCT/KR2021/003537 WO2021210799A1 (ko) | 2020-04-13 | 2021-03-23 | 피라졸 유도체의 폐섬유증 치료제 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3172596A1 true CA3172596A1 (en) | 2021-10-21 |
Family
ID=78083982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3172596A Pending CA3172596A1 (en) | 2020-04-13 | 2021-03-23 | Pulmonary fibrosis medicine containing pyrazole derivative |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12616684B2 (enExample) |
| EP (1) | EP4137134A4 (enExample) |
| JP (1) | JP7539485B2 (enExample) |
| KR (2) | KR102567012B1 (enExample) |
| CN (1) | CN115427039B (enExample) |
| AU (1) | AU2021255160B2 (enExample) |
| BR (1) | BR112022020649A2 (enExample) |
| CA (1) | CA3172596A1 (enExample) |
| CL (1) | CL2022002642A1 (enExample) |
| CO (1) | CO2022014273A2 (enExample) |
| MX (1) | MX2022012726A (enExample) |
| WO (1) | WO2021210799A1 (enExample) |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040094464A (ko) * | 2003-05-02 | 2004-11-10 | 학교법인 이화학당 | 피리디닐 피라졸 유도체 |
| KR20120054077A (ko) | 2009-08-21 | 2012-05-29 | 길리아드 바이오로직스, 인크. | 폐 섬유증 장애의 치료를 위한 방법 및 조성물 |
| WO2011028043A2 (ko) | 2009-09-02 | 2011-03-10 | 이화여자대학교 산학협력단 | 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물 |
| KR101302315B1 (ko) * | 2011-07-19 | 2013-08-30 | 이화여자대학교 산학협력단 | 피라졸 유도체를 포함하는 호흡기 질환 예방 및 치료용 조성물 |
| KR101633957B1 (ko) | 2012-08-27 | 2016-06-27 | 이화여자대학교 산학협력단 | 피라졸 유도체를 포함하는 신장질환 예방 또는 치료용 조성물 |
| US10548911B2 (en) * | 2014-06-16 | 2020-02-04 | University Of Rochester | Small molecule anti-scarring agents |
| US11096952B2 (en) * | 2016-02-02 | 2021-08-24 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Chemicals and methods to prevent and treat TGF-beta mediated activation of fibroblasts to reduce and treat cancer and fibrosis |
| WO2017192304A1 (en) | 2016-05-02 | 2017-11-09 | Inception 1, Inc. | Arylcarboxamides and uses thereof |
| CA3046158A1 (en) | 2017-01-27 | 2018-08-02 | Genfit | Pharmaceutical compositions for combination therapy |
| KR101821593B1 (ko) | 2017-02-23 | 2018-01-25 | 압타바이오 주식회사 | 안질환 치료제 |
| IL268751B (en) | 2017-03-13 | 2022-08-01 | Genfit | Pharmaceutical preparations for combined treatment |
| CN110536683A (zh) | 2017-04-18 | 2019-12-03 | 基恩菲特公司 | 包含PPAR激动剂如伊拉非诺和乙酰CoA羧化酶ACC抑制剂的组合 |
| KR101856444B1 (ko) | 2017-04-20 | 2018-05-10 | 압타바이오 주식회사 | 3-페닐-4-프로필-1-(피리딘-2-일)-1ｈ-피라졸-5-올 염산염의 신규 결정형 고체 화합물 |
| KR101840702B1 (ko) * | 2017-11-01 | 2018-03-22 | 압타바이오 주식회사 | 간질환 치료제 |
| TWI815938B (zh) | 2018-08-01 | 2023-09-21 | 日商日本化藥股份有限公司 | 具有n-烷基的芳香族胺樹脂、硬化性樹脂組成物及其硬化物 |
| EP3628669A1 (en) | 2018-09-28 | 2020-04-01 | GenKyoTex Suisse SA | Novel compounds as nadph oxidase inhibitors |
| KR102207340B1 (ko) | 2018-10-19 | 2021-01-22 | 한남대학교 산학협력단 | 표면 개질된 다공성 탄소복합소재 및 그 제조방법 |
| CN109912600B (zh) * | 2019-02-22 | 2021-08-03 | 四川大学华西医院 | 一种防治肺纤维化的咪唑并嘧啶类衍生物及其应用 |
| MX2022012472A (es) | 2020-04-08 | 2022-12-15 | Aptabio Therapeutics Inc | Agente para el tratamiento de lesion renal aguda inducida por medio de contraste. |
| WO2021263281A2 (en) * | 2020-06-26 | 2021-12-30 | Ann And Robert H. Lurie Children's Hospital Of Chicago | Methods and compositions for the treatment of covid-19 and associated respiratory distress and multi-organ failure, sepsis, acute respiratory distress syndrome, and cordiovascular diseases |
| UY39671A (es) | 2021-03-15 | 2022-10-31 | Novartis Ag | Derivados de pirazolopiridina y sus usos. |
-
2021
- 2021-03-23 MX MX2022012726A patent/MX2022012726A/es unknown
- 2021-03-23 CN CN202180028319.3A patent/CN115427039B/zh active Active
- 2021-03-23 EP EP21787824.8A patent/EP4137134A4/en active Pending
- 2021-03-23 JP JP2022562440A patent/JP7539485B2/ja active Active
- 2021-03-23 CA CA3172596A patent/CA3172596A1/en active Pending
- 2021-03-23 AU AU2021255160A patent/AU2021255160B2/en active Active
- 2021-03-23 BR BR112022020649A patent/BR112022020649A2/pt unknown
- 2021-03-23 WO PCT/KR2021/003537 patent/WO2021210799A1/ko not_active Ceased
- 2021-03-23 US US17/918,497 patent/US12616684B2/en active Active
- 2021-11-24 KR KR1020210162964A patent/KR102567012B1/ko active Active
-
2022
- 2022-03-16 KR KR1020220032891A patent/KR20220039687A/ko active Pending
- 2022-09-27 CL CL2022002642A patent/CL2022002642A1/es unknown
- 2022-10-05 CO CONC2022/0014273A patent/CO2022014273A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021210799A1 (ko) | 2021-10-21 |
| JP7539485B2 (ja) | 2024-08-23 |
| KR20210146871A (ko) | 2021-12-06 |
| EP4137134A1 (en) | 2023-02-22 |
| US20230148365A1 (en) | 2023-05-11 |
| MX2022012726A (es) | 2022-11-07 |
| KR20220039687A (ko) | 2022-03-29 |
| CN115427039B (zh) | 2025-04-04 |
| BR112022020649A2 (pt) | 2022-11-29 |
| AU2021255160B2 (en) | 2024-02-01 |
| JP2023522628A (ja) | 2023-05-31 |
| CL2022002642A1 (es) | 2023-06-16 |
| EP4137134A4 (en) | 2024-08-07 |
| KR102567012B1 (ko) | 2023-08-14 |
| CO2022014273A2 (es) | 2022-10-21 |
| AU2021255160A1 (en) | 2022-10-06 |
| US12616684B2 (en) | 2026-05-05 |
| CN115427039A (zh) | 2022-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7492002B2 (ja) | Ｌｓｄ１阻害剤によりｌｓｄ１関連疾患及び障害を治療する方法 | |
| KR102347721B1 (ko) | 섬유성 질환의 치료에 사용하기 위한 ppar 화합물 | |
| JP7745584B2 (ja) | ５’－アデノシン二リン酸リボース（ａｄｐｒ）の使用方法 | |
| KR102647942B1 (ko) | 섬유증 치료제 | |
| EP4272832A2 (en) | Antimicrobial compounds, compositions, and uses thereof | |
| KR20230121890A (ko) | 섬유증 치료 방법 | |
| JP5457196B2 (ja) | Ｃｎｄａｃ（２’−シアノ−２’−デオキシ−ｎ４−パルミトイル−１−ベータ−ｄ−アラビノフラノシル−シトシン）及び細胞毒性薬を含む組合せ | |
| AU2021255160B2 (en) | Pulmonary fibrosis medicine containing pyrazole derivative | |
| KR102386097B1 (ko) | 피라졸 유도체의 폐섬유증 치료제 | |
| RU2817989C1 (ru) | Средство для лечения фиброза легких, содержащее производное пиразола | |
| JP7749661B2 (ja) | 心不全の処置のためのクロマノール化合物 | |
| KR20210084442A (ko) | 포도막 흑색종 치료를 위한 병용 요법 | |
| CN106999468B (zh) | 熊脱氧胆酸和水飞蓟素改进cpt-11疗效和毒性的制药用途 | |
| EP1908473B1 (en) | Clarithromycin or salt thereof for use in the treatment pulmonary emphysema | |
| KR20220000460A (ko) | 폐섬유화증 치료용 조성물 | |
| US20210260153A1 (en) | Use of cyclosporine analogues for treating fibrosis | |
| JPWO2002085363A1 (ja) | 糸球体疾患治療剤 | |
| US10364230B2 (en) | Chromene-2 derivatives and use thereof in the treatment of fibrosis | |
| CN116270663A (zh) | 胆汁酸及其衍生物在治疗呼吸道炎症性疾病中的应用 | |
| WO2020045475A1 (ja) | ピラゾロ［３，４－ｄ］ピリミジンの結晶 | |
| US20100179324A1 (en) | Anti-tumor agent comprising sulphostin or sulphostin-related compound as the active ingredient | |
| MX2007016109A (es) | Claritromicina o sal de la misma para usarse en el tratamiento o prevencion de enfermedad pulmonar inducida por destruccion de los alveolos pulmonares. | |
| HK1122209A (en) | Clarithromycin or salt thereof for use in the treatment or prevention of pulmonary disease induced by destruction of pulmonary alveoli |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220921 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20240829 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241217 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241217 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241217 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20241224 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250217 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250614 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250614 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260310 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260321 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260323 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260326 |